HomeCompareEFTR vs DIVO

EFTR vs DIVO: Dividend Comparison 2026

EFTR yields 1000000.00% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EFTR wins by $4.7683925249533696e+36M in total portfolio value
10 years
EFTR
EFTR
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full EFTR calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — EFTR vs DIVO

📍 EFTR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEFTRDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EFTR + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EFTR pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EFTR
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, EFTR beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EFTR + DIVO for your $10,000?

EFTR: 50%DIVO: 50%
100% DIVO50/50100% EFTR
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EFTR right now

EFTR
Analyst Ratings
6
Buy
Consensus: Buy
Price Target
$5.50
+2749900.0% upside vs current
Range: $1.00 — $10.00
Altman Z
-13.6
Piotroski
2/9
DIVO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EFTR buys
0
DIVO buys
0
No recent congressional trades found for EFTR or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEFTRDIVO
Forward yield1000000.00%6.49%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.7683925249533696e+36M$30.7K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$981.68
Total dividends collected$4.7683311610149396e+36M$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: EFTR vs DIVO ($10,000, DRIP)

YearEFTR PortfolioEFTR Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,349$649.42+$100.00MEFTR
2$934,786,450,701$934,679,439,252.34$12,833$688.83+$934786.44MEFTR
3$8,165,787,108,578,292$8,164,786,887,076,042.00$14,459$727.90+$8165787108.56MEFTR
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$16,238$766.49+$66665884190957.63MEFTR
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$18,179$804.47+$508662171058048128.00MEFTR
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$20,293$841.71+$3.62723524842849e+21MEFTR
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$22,591$878.14+$2.417368115915061e+25MEFTR
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$25,087$913.65+$1.5056740286145463e+29MEFTR
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$27,791$948.18+$8.764771002818475e+32MEFTR
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$30,718$981.68+$4.7683925249533696e+36MEFTR

EFTR vs DIVO: Complete Analysis 2026

EFTRStock

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.

Full EFTR Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this EFTR vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EFTR vs SCHDEFTR vs JEPIEFTR vs OEFTR vs KOEFTR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.